Eczema Matters is an online magazine that features the latest info on eczema and atopic dermatitis treatment, causes and research for children and adults.
Today, the U.S. Food and Drug Administration approved Eucrisa (crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD). Eucrisa works differently than other topical treatments on the market. It is not a steroid or a topical calcineurin inhibitor.
The first, crisaborole, is an ointment that reduces itching, redness and swelling of the skin. It is the first anti-inflammatory medication to be approved for the treatment of mild to moderate AD in more than 15 years. It is approved for patients 2 years of age or older.
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable.
The FDA recently approved a novel drug, crisaborole (Eucrisa), for the treatment. and inflammation caused by atopic dermatitis, which is also known as eczema.. is unavailable at this time, but the product should be available in early 2017.
TUESDAY, March 28, 2017 (HealthDay News) — Adults plagued by eczema may have a new treatment option, with a new drug approved Tuesday by the U.S. .